

# Apple Health (Medicaid) COVID-19 testing clinical policy

In this time of the COVID-19 pandemic, the Health Care Authority is aware that usual and customary ways of providing and billing/reporting services may not be feasible. It is also understood that different providers will have different capabilities. Therefore, in the interest of public health, HCA's Apple Health (Medicaid) program is trying to be as flexible as possible and is creating new policies that will allow you to provide medically necessary services and bill or report the encounter with the most appropriate code you determine applicable, using the guidance below.

This FAQ reinforces the agency's current policies regarding telemedicine as defined in <u>WAC 182-531-1730</u> and covers the new telehealth policies that will only be in effect during this health care crisis. We will update this FAQ as necessary to respond to new information as it develops.

The FAQ below was revised after new information was released Friday, March 20, by the Centers for Medicare & Medicaid Services (CMS) in an all-state call about the use of telehealth in Medicaid. Note: Medicaid is not subject to the same policies as Medicare.

### Overview

The Medicaid program pays for Coronavirus disease 2019 (COVID-19) molecular, antigen and antibody testing for medically necessary diagnostic services ordered by a qualified provider.

Qualified providers are those who are eligible to bill Medicaid for reimbursement, such as health care providers, pharmacists, and dentists as listed in Washington Administrative Code (WAC) Chapter 182-502 WAC.

Only tests with FDA approval or FDA Emergency Use Authorization (EUA) are reimbursed when medically necessary in accordance with Chapter 182-530 WAC.

Providers that perform COVID-19 testing are expected to meet the <u>Washington State Department of Health</u> <u>Reporting Requirements</u> and have the appropriate credentials to perform testing.

Please see the COVID-19 fee schedule for rates. This policy applies to HCA-contracted managed care organizations

| PCR Tests     |                              |                        |                                   |  |  |  |  |
|---------------|------------------------------|------------------------|-----------------------------------|--|--|--|--|
| HCPCS<br>Code | Short Description            | Professional<br>Claims | Facility Claims                   |  |  |  |  |
| U0001         | 2019-ncov diagnostic p       | Modifier CR            | Modifier CR and Condition code DR |  |  |  |  |
| U0002         | Covid-19 lab test non-cdc    | Modifier CR            | Modifier CR and Condition code DR |  |  |  |  |
| U0003         | Cov-19 amp prb hgh thruput   | Modifier CR            | Modifier CR and Condition code DR |  |  |  |  |
| U0004         | Cov-19 test non-cdc hgh thru | Modifier CR            | Modifier CR and Condition code DR |  |  |  |  |
| CPT®<br>Code  | Short Description            | Professional<br>Claims | Facility Claims                   |  |  |  |  |
| 87635         | SARS-COV-2 COVID-19 AMP PRB  | Modifier CR            | Modifier CR and Condition code DR |  |  |  |  |



| 87636        | SARSCOV2 & INF A&B AMP PRB   | Modifier CR | Modifier CR and Condition code DR |  |  |  |
|--------------|------------------------------|-------------|-----------------------------------|--|--|--|
| 87637        | SARSCOV2&INF A&B&RSV AMP PRB | Modifier CR | Modifier CR and Condition code DR |  |  |  |
| Antigen test |                              |             |                                   |  |  |  |
| 87426        | CORONAVIRUS AG IA            | Modifier CR | Modifier CR and Condition code DR |  |  |  |
| 87811        | SARS-COV-2 COVID19 W/OPTIC   | Modifier CR | Modifier CR and Condition code DR |  |  |  |
| 87428        | SARSCOV & INF VIR A&B AG IA  | Modifier CR | Modifier CR and Condition code DR |  |  |  |

### Billing for specimen collection

When collecting a specimen to test for COVID-19 that is not associated with an E/M visit, HCA previously allowed CPT® code 99001 to be billed. Effective 10/1/2020, in order to align with Medicare and other payers, Apple Health will allow HCPCS code G2023, G2024, and C9803 when billing for specimen collection, which includes drive-through testing. Those procedure codes will retro back to the date listed on the COVID-19 Fee Schedule and Apple Health will accept CPT® code 99001 with a date of service before 10/15/2020 only. If you have denials for the following procedure codes, please resubmit your claim.

Please note HCPCS code G2023 and G2024 are not encounter eligible for federally qualified health centers (FQHCs) and rural health clinics (RHCs). CPT® 99211 is encounter eligible when performed by an encounter eligible provider in an eligible place of service. Outpatient hospital specimen collection, HCPCS code C9803, is not allowable in the FQHC or RHC setting.

The codes listed below are eligible for the IHS (Indian Health Services) encounter rate if rendered by a health care professional at a direct IHS clinic, tribal clinic or tribal FQHC.

| Specimen collection |                            |                            |                   |  |  |  |
|---------------------|----------------------------|----------------------------|-------------------|--|--|--|
| <b>HCPCS Code</b>   | Description                | <b>Professional Claims</b> | Facility Claims   |  |  |  |
| G2023               | Specimen collect covid-19  | Modifier CR                | Modifier CR and   |  |  |  |
|                     |                            |                            | Condition code DR |  |  |  |
| C9803               | Hopd covid-19 spec collect | Modifier CR                | Modifier CR and   |  |  |  |
|                     |                            |                            | Condition code DR |  |  |  |
| CPT® Code           | Short Description          | Professional Claims        | Facility Claims   |  |  |  |
| 99211               | Office Specimen Collection | Modifier CR                | Modifier CR and   |  |  |  |
|                     |                            |                            | Condition code DR |  |  |  |

## Clinical Policy: Medical Necessity Criteria for Antibody Testing for SARS-CoV-2 Policy

Antibody testing currently has clinical applicability only in specific circumstances and is not recommended for the general public on a broad scale. Per CDC Interim Guidelines for COVID-19, antibody testing should not be used to determine immune status in individuals until the presence, durability, and duration of immunity is established.

Based on this information, the Health Care Authority requires the following criteria be met for payment of COVID-19 antibody tests:

Must be performed by a CLIA certified lab

Must meet medical necessity criteria, specifically that the results from the antibody test will be used by a clinician to initiate or change the management of a client's care. A representative example of this occurs in cases



where a client has late complications of COVID-19 illness, such as multisystem inflammatory syndrome in children

Please note, this policy may be updated as new information becomes available. This policy has a retroactive date of 4/10/20. HCA may perform a post-pay review on any claim and supporting physician's documentation to ensure compliance with this policy.

| Antibody Test |                              |                     |  |   |  |  |  |
|---------------|------------------------------|---------------------|--|---|--|--|--|
| CPT® code     | Short Description            | Professional claims | Facility<br>Claims                         | Limitation  |  |  |  |
| 86328         | IA NFCT AB SARSCOV2 COVID19  | Modifier CR         | Modifier CR<br>and<br>Condition<br>code DR | 1 antibody test<br>per calendar<br>year, per client |  |  |  |
| 86408         | NEUTRLZG ANTB SARSCOV2 SCR   | Modifier CR         | Modifier CR<br>and<br>Condition<br>code DR | 1 antibody test<br>per calendar<br>year, per client |  |  |  |
| 86409         | NEUTRLZG ANTB SARSCOV2 TITER | Modifier CR         | Modifier CR<br>and<br>Condition<br>code DR | 1 antibody test<br>per calendar<br>year, per client |  |  |  |
| 86413         | SARS-COV-2 ANTB QUANTITATIVE | Modifier CR         | Modifier CR<br>and<br>Condition<br>code DR | 1 antibody test<br>per calendar<br>year, per client |  |  |  |
| 86769         | SARS-COV-2 COVID-19 ANTIBODY | Modifier CR         | Modifier CR<br>and<br>Condition<br>code DR | 1 antibody test<br>per calendar<br>year, per client |  |  |  |

Apple Health (Medicaid) is aware that there are other non-specific procedure codes that could be used to gain the same information, if those codes are billed to Apple Health (Medicaid) the same criteria listed above will be applied.

#### Limitations:

• Limited to 1 antibody test per calendar year per client. If additional test are needed, providers can submit a limitation extension request to HCA. Please see the <a href="Physician related services/health care">Physician related services/health care</a> professional services billing guide for information regarding limitation extension.

### Fee Schedule:

• Please see HCA's COVID-19 fee schedule.